Bio­Marin taps AI up­start Deep Ge­nomics for dis­cov­ery pact; Prax­is says it has a path to lift­ing clin­i­cal hold

Years af­ter dou­ble FDA/EMA re­jec­tions left Bio­Marin’s oligonu­cleotide for Duchenne mus­cu­lar dy­s­tro­phy lan­guish­ing on the shelf, the com­pa­ny is go­ing back to the draw­ing board for new oligonu­cleotide drug can­di­dates — with a healthy dose of ar­ti­fi­cial in­tel­li­gence.

Its part­ner of choice is Deep Ge­nomics, a Toron­to-based shop led by star re­searcher Bren­dan Frey. Paid an undis­closed up­front, their man­date is to iden­ti­fy and val­i­date new tar­get mech­a­nisms in rare dis­eases as well as lead can­di­dates. Bio­Marin will then take over the pre­clin­i­cal work.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.